Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Доклад, представленный на ежегодной конференции Американского общества клинической онкологии (ASCO), 13–17 мая 2005 г., Орландо, штат Флорида, США
Доклад, представленный на ежегодной конференции Американского общества клинической онкологии (ASCO), 13–17 мая 2005 г., Орландо, штат Флорида, США
Доклад, представленный на ежегодной конференции Американского общества клинической онкологии (ASCO), 13–17 мая 2005 г., Орландо, штат Флорида, США. Онкология. 2006; 2: 32-35.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Фемара улучшает безрецидивную выживаемость больных раком молочной железы: результаты клинического исследования BIG-I-98
Полный текст
Список литературы
1. Fisher et al. Threatment of lymph-node-negative oestrogen-receptor-positive breast cancer: long-term findings from national surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004; 364: 858–68.
2. Winer EP et al. American Society of clinical Oncology technology assessment of the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cencer. Status report 2002. J Clin Oncol 2002; 20: 3317–27.
3. Fusher B et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer. Updated findings form the National Surgical Adjuvant breast and bowel project B-14: randomized trial. J Natl Cancer Inst 2001; 93: 684–90.
4. ATAC trialists' Group. Anastrzole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with carly-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in combination) trial efficacy and safety update analyses. Cancer 2003; 98: 1802–10.
5. ANAC trialsts'Group. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 year's adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2.
6. Scottish Cancer Trials Office (MRC): Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet 1987; 330: 171–5.
7. Stewart HJ, for the Scottish Breast Group. Adjuvant tamoxifen duration in a randomized trial. Breast 1995; 4: 256.
8. Early Breast Cancer Trialists' CollaborativeGroup. Polychemotherapy for carly breast cancer: An overview of the randomised trials. Lancet 1998; 352: 930–42.
9. Wasan KM et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen. (NCIC CTG MA. 17L). Ann Oncol 2005; 16: 707–15.
10. Brufsky A et al. Zoledronic acid effectively inhibits cancer treatment-induced bone loss in Postmenopausal women with carly breast cancer recciving adjuvant letrozole: 12-month BMD results of the Z-fast trial. Data presented at the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO). Orlando, FL, USA (Abstract 533).
2. Winer EP et al. American Society of clinical Oncology technology assessment of the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cencer. Status report 2002. J Clin Oncol 2002; 20: 3317–27.
3. Fusher B et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer. Updated findings form the National Surgical Adjuvant breast and bowel project B-14: randomized trial. J Natl Cancer Inst 2001; 93: 684–90.
4. ATAC trialists' Group. Anastrzole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with carly-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in combination) trial efficacy and safety update analyses. Cancer 2003; 98: 1802–10.
5. ANAC trialsts'Group. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 year's adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2.
6. Scottish Cancer Trials Office (MRC): Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet 1987; 330: 171–5.
7. Stewart HJ, for the Scottish Breast Group. Adjuvant tamoxifen duration in a randomized trial. Breast 1995; 4: 256.
8. Early Breast Cancer Trialists' CollaborativeGroup. Polychemotherapy for carly breast cancer: An overview of the randomised trials. Lancet 1998; 352: 930–42.
9. Wasan KM et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen. (NCIC CTG MA. 17L). Ann Oncol 2005; 16: 707–15.
10. Brufsky A et al. Zoledronic acid effectively inhibits cancer treatment-induced bone loss in Postmenopausal women with carly breast cancer recciving adjuvant letrozole: 12-month BMD results of the Z-fast trial. Data presented at the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO). Orlando, FL, USA (Abstract 533).
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.